Articles About The Tech Sector

Investor Confidence is Back, Here’s Who to Buy in 2020 to Cash In

0 | By Strategic Tech Investor Staff

Without semiconductors, there is no American economy. That’s because the American economy is driven by tech, and tech is driven by semiconductors. After an outstanding jobs report, big media is finally coming around to my point of view that tech investors have lot of upside ahead, and very few reasons to be worried. In times like these, it’s important to look for the pick-and-shovel plays that will be supporting development in as many breakout sectors as possible. The right semiconductor plays will be able to profit from the rollout of 5g wireless, along with advances such as cobots, robots that cooperate with humans in the workplace. With new breakouts just around the corner in 2020, you’re not going to want to miss the firms that will be holding it all together. Click here to watch.

Why Trump’s Reelection is Looking More Likely

0 | By Michael A. Robinson

I’ll never forget sailing with my buddies on San Francisco Bay back in the summer of 2016.

Both are high-tech investors who were absolutely convinced that Donald J. Trump had exactly zero chance of becoming president.

But I strongly disagreed. That’s because I follow these things closely since big political elections can affect the stock market, not to mention every sector of the economy, including high tech.

On top of all that, I was a young auto analyst in Detroit back in 1980 when Ronald Reagan was elected. I personally talked with union members who crossed party lines and helped put Reagan in the White House.

I told my sailing buddies that the same dynamic was at work in 2016. I didn’t just predict that Trump would win, I walked them through several of the key districts and showed them exactly how he would do it.

Here I go again…I believe that Trump now has a much better chance of getting reelected than he did before the Democratic-led impeachment hearings began.

And with the economic situation set to continue on course, that’s good news for investors. We’re going to be seeing a lot of new wealth created by a lot of cutting-edge technology

A Holiday Heads-up From Michael Robinson

0 | By Michael A. Robinson

Trading volume is going to be thin today, due to the holiday, so I wanted to take this chance to say that I I am thankful for the support of my team and more importantly you the reader. I hope you all had a happy Thanksgiving.

I’ll still be keeping one eye on the market today, watching for key developments. I’ll be back next week to report on what I’ve noticed, and give my recommendations as the market heads into the final month of this year

Five Rules for Scoring Gains While Wall Street’s Stuck on Trade War News

0 | By Michael A. Robinson

There’s a memo going around Wall Street.

It says to stay away from investing in Chinese stocks during our trade battles with that nation.

It’s a good thing that someone forgot to give Daniel Zhang a copy.

Here’s the thing. While tariffs the U.S. imposed on some Chinese goods have slowed factory output over there, that has hardly filtered down to the nation’s thriving Web sector.

And that’s where Zhang is really shining right now. He’s the CEO of Internet giant Alibaba Group Holding Ltd. (BABA) and just pulled off a remarkable coup.

In the first hour of the firm’s recent Single’s Day shopping bonanza Nov. 11, it brought in $13 billion. No, that’s not a misprint. Alibaba sold more goods in 60 minutes than hundreds of U.S. firms do in a year.

By contrast, that’s roughly 80% of what Amazon.com Inc. (AMZN) pulled in last quarter.

With that in mind, today I going to reveal five reasons why this stock will continue to beat the broad U.S. market by more than 30% a year

Get in On This Medical Breakthrough Before It Hits the Market

1 | By Michael A. Robinson

Imagine if all it took to treat a case of cancer was taking out the trash.

Now I want you to imagine that your body could do it all for you.

Hold that thought. Because a tech platform with that very task in mind is set to hit the market sooner than you think and will target a field set to be worth more than $160 billion.

Here’s the thing. Several life sciences firms are hard at work perfecting a new class of drugs known as “degraders.”

Let me explain. The root of many diseases lies in misguided proteins that bind together. So, the idea here is to come up with a new class of drugs that activate the body’s own molecular trash disposal systems.

This is one of the most exciting breakthroughs I’ve come across in many years. I believe it puts us close to the day when one pill can cure dozens, if not all, diseases.

And in a moment, I’m going to reveal a way investors can target the entire class of protein degraders with one savvy move

You Can Double Your Money Fighting the $1.1 Trillion Disease Killing America

0 | By Michael A. Robinson

I recently got the kind of news that no child wants to hear about an aging parent.

Here’s the thing, I count my blessings that my dad lived so long. After all, he’s a retired Marine Corps captain who saw three tours of combat, one in Korea and two in Vietnam.

Honestly he’s lucky he lived as long as he did. But that still doesn’t make the aging process any easier, at least not on the body.

He recently had a second knee replacement that didn’t go as well as planned. He also has swelling of the feet. His mobility is not all that great, and he can’t drive right now.

At 86, he recently learned he has congestive heart failure. That’s a condition in which the heart doesn’t pump as strongly as it should, leading to a buildup of fluids.

As such, my dad is part of a huge trend in America. Fact is, according to the American Heart Association, cardiovascular disease is set to have an economic impact of $1.1 trillion by 2035.

And today, I want to reveal a life sciences firm that is bringing badly needed relief to millions of heart patients, and show you five reasons why it’s set to double in as little as 3.5 years

The Answer to Big Pharma’s Biggest Problem Could Double Your Money in just Three Years

0 | By Michael A. Robinson

You could forgive drug and biotech executives for having a bad case of target fixation.

After all, they do work in a field that is filled with time-consuming and expensive headaches.

Consider that the Biotechnology Innovation Organization (BIO), the world’s largest biotech trade organization, looked at 7,400 drug programs by 1,103 companies. They were investigating drug-approval rates.

The news was not good -just 9.6% of drugs scientists discover ever get approved for sale. That’s a one-in-ten shot.

With such daunting data, it’s no wonder that, even in a field already worth $1.2 trillion in global sales, industry leaders are on the lookout for ways to lower the cost of discovery and shorten time to market.

And with that goal in mind, I’ve uncovered a high-octane, large-cap firm that has become an essential ingredient in the drug sector’s success.

It’s a cloud-based leader in pharmaceutical efficiency that has a history of crushing the market by no small measure. It’s been doubling its earnings, on average, every 18 months

It’s a cloud-based leader in pharmaceutical efficiency that has a history of crushing the market by no small measure. It’s been doubling its earnings, on average, every 18 months

My Top Three Recommendations for New Investors

0 | By Michael A. Robinson

My “dad vibe” must be working overtime these days.

And that’s got me thinking maybe my “chance” conversations with a number of young adults lately is a sign of the times.

Let me explain.

As I’ve been going about my routines in the past, I’ve run into a lot of young people who want to get started in investing, but have no clue how to do so.

I’m talking about folks my daughters’ age who are earning some income and want to invest, but just don’t know where to start.

For instance, once, while skiing at the Kirkwood Mountain Resort near Lake Tahoe, I chatted with three young adults who jumped at the chance to get my advice about investing.

I guess that’s where the dad vibe comes into play…. I told them about a surefire way to make the market work for them as though I were talking to my own daughters.

And it just so happens that this investment advice is good for newcomers and old, particularly investors who’ve been reluctant to jump in when market conditions are so volatile.

That’s why today, I’m going to show you not just the one “starter” investment vehicle I suggest for young adults that can set you on the right track…

But I’m going to recommend three other tech-centric ways to jump start your portfolio right now…

Check it out

The “Printing” Tech Tackling Heart Disease’s $400 Billion in Annual Costs

0 | By Michael A. Robinson

There’s a new cutting-edge tech breakthrough that could save the lives of six million Americans in a decade.

Yes, it is potentially a very powerful weapon in the fight against heart disease, which the U.S. Centers for Disease Control and Prevention says causes one in four deaths each year.

Ironically, the technology is in a sector deeply out of favor with Wall Street.

But that’s just fine with us. At Strategic Tech Investor, we know the huge profit potential in bucking the Street’s herd mentality.

And you couldn’t pick a more exciting field than 3D-printed human organs.

Here’s the thing. Scientists in Israel printed a tiny heart in April, complete with blood vessels, using a patient’s cells.

Even better, they pulled off this amazing achievement in just three hours.

That’s why today, I’m going to show you what I believe is the best market-crushing play on the future of 3D printing tech used to save lives…

Check it out